Who's in favor of translational cell therapy for stroke: STEPS forward please? - PubMed (original) (raw)

Who's in favor of translational cell therapy for stroke: STEPS forward please?

Michael Chopp et al. Cell Transplant. 2009.

Abstract

A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Bliss TM, Kelly S, Shah AK, Foo WC, Kohli P, Stokes C, Sun GH, Ma M, Masel J, Kleppner SR, Schallert T, Palmer T, Steinberg GK. Transplantation of hNT neurons into the ischemic cortex: Cell survival and effect on sensorimotor behavior. J. Neurosci. Res. 2006;83:1004–1014. - PubMed
    1. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke. 2004;35:2385–2389. - PubMed
    1. Borlongan CV, Tajima Y, Trojanowski JQ, Lee VM, Sanberg PR. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp. Neurol. 1998;149:310–321. - PubMed
    1. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005–1011. - PubMed
    1. Hänsch GM, Hammer CH, Vanguri P, Shin ML. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc. Natl. Acad. Sci. USA. 1981;78:5118–5121. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources